01

Nov2019

CanReValue RWE Webinar & Feedback Opportunity

Mark your calendar: On Wednesday, November 6th at 11:00 a.m., the Canadian Real-World Evidence for Value of Cancer Drugs (CanReValue) team will host a webinar to present the development and testing of a framework that will be used to generate and apply real-world evidence (RWE) in funding decisions for ... Read More

31

Oct2019

INFOGRAPHIC: The Truth About the Federal Drug Pricing Reform

3Sixty Public Affairs and PDCI Market Access have collaborated to create an infographic that unmasks the reality behind the assumptions Health Canada has used to justify its ongoing drug pricing reforms (through the Patented Medicine Prices Review Board). When it comes to federal drug pricing reform in Canada, there is ... Read More

25

Oct2019

Keeley Farrell Joins PDCI Market Access!

PDCI is very pleased to welcome Keeley Farrell to the PDCI Team as Analyst, HTA and Clinical Evaluation. Keeley will help to support the development and preparation of the evidence-based clinical components of reimbursement and pricing submissions. She will also conduct research to support market access and ... Read More

24

Oct2019

STATUS SUMMARY OF INNOVATIVE MEDICINE pCPA NEGOTIATIONS AS OF SEPTEMBER 30, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest.  SUMMARY OF NEW PCPA ACTIVITY SINCE AUGUST ... Read More

07

Oct2019

PDCI Response to 2019 CADTH Consultations

In July 2019, CADTH announced a new round of public consultations on its Pharmaceutical Review Programs. CADTH’s proposed changes would affect how it manages, reviews and reconsiders information submitted by pharmaceutical manufacturers through its Common Drug Review. Stakeholders were invited to submit feedback on three consultations: Proposal to Enhance ... Read More

12

Sep2019

PDCI Market Access: PMPRB Workshops (Toronto and Montreal)

REGISTRATION IS OPEN! Learn how the new PMPRB amendments and guidelines will affect your pharmaceutical pricing, negotiations and reimbursement Join PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, for industry-only sessions on the pricing guidelines, led by senior members of the PDCI team ... Read More

03

Sep2019

Waleed Adebayo Joins PDCI Market Access!

PDCI is very pleased to welcome Waleed Adebayo to the PDCI Team as Assistant, Pricing Data Research, effective September 3, 2019. Waleed holds a Bachelor of Economics from Carleton where he is also completing a BSc in Statistics (expected April 2020).  He has experience doing data research both at Statistics Canada ... Read More

30

Aug2019

CADTH Releases Pharmaceutical Reviews Update 10

CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review processes updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information on this review, please consult the CADTH website. CADTH has extended the ... Read More

27

Aug2019

UPCOMING WEBINAR SEPTEMBER 4: 2019 PMPRB Regulation Amendments and Implications

PDCI and 3Sixty Public Affairs invites its industry clients, partners and colleagues to participate in a webinar on September 4, 2019 between 2:00pm to 3:00pm. This important session will cover the PMPRB price regulatory amendments and share insights on their implications for pharmaceutical market access. The session will provide an overview of ... Read More

19

Aug2019

HDAP 2020 Meeting Dates Released

The PMPRB has announced the 2020 meeting dates to the Human Drug Advisory Panel (HDAP)’s , releasing a total of four (4) dates, as per previous years. This corrected version of TargetPharma makes a distinction between the deadline for submitting the Product Monograph and the deadline for the Patentee's submission.... Read More